Pay in 4 interest-free payments of $5.11 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
Findings also show improved persistence with high-potency, obesity-approved GLP-1 products EAGAN, Minn., June 25, 2025 /PRNewswire/ -- Only 8% of individuals (or 1 in 12) initiating a glucagon-like peptide-1 (GLP-1) agonist drug for obesity without diabetes continued to do so at three years, according to the latest real-world research from pharmacy solutions partner Prime Therapeutics LLC (Prime)
NICE guidance supports their use as part of NHS services for selected patients
It can help individuals with obesity or overweight shed extra pounds, leading to improved overall health and a reduced risk of obesity-related diseases such as type 2 diabetes, cardiovascular disease, and certain types of cancer
Keep a simple log if it helps you remember where you last injected
